Internal Medicine, Medical Oncology · Inverness, FL
NPI
1154598068
Since 2008
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
2231 Highway 44 W Ste 203
Inverness, FL, 34453
Phone (352) 860-7400
Groups this clinician bills Medicare through
Medicare paid, 2024
$6.5M
385,301 services
Medicare patients, 2024
1,494
Average age 76
Drug cost, 2024
$5.3M
1,741 prescriptions
Company payments, 2025
$2,489
From 36 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Susmitha Apuri was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 62,220 times for 74 patients. In total Susmitha Apuri billed 385,301 services in 170 codes, and Medicare paid $6.5M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-03-24.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 62,220 | 74 | $0.28 | $17K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 32,800 | 23 | $44.63 | $1.5M |
| Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 20,220 | 24 | $0.22 | $4,386 |
| J0897 Injection, denosumab, 1 mg | Office | 12,960 | 143 | $20.52 | $266K |
| J9267 Injection, paclitaxel, 1 mg | Office | 9,692 | 13 | $0.08 | $784 |
| J0185 Injection, aprepitant, 1 mg | Office | 8,060 | 22 | $1.33 | $11K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 7,420 | 69 | $6.30 | $47K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 5,600 | 43 | $15.98 | $89K |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 5,372 | 21 | $35.98 | $193K |
| Q5101 Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Office | 5,100 | 11 | $0.24 | $1,233 |
| J1434 Injection, fosaprepitant (focinvez), 1 mg | Office | 4,800 | 12 | $2.36 | $11K |
| 36415 Venipuncture Blood Collection | Office | 4,016 | 1,262 | $8.65 | $35K |
| 85025 Blood Count | Office | 3,988 | 1,229 | $7.61 | $30K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 3,385 | 57 | $0.09 | $306 |
| Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 2,603 | 15 | $32.09 | $84K |
By year: 2022 $3.5M for 301,783 services; 2023 $4.6M for 365,237 services; 2024 $6.5M for 385,301 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 4,016 | 1,262 | $8.65 | $35K |
| 85025 Blood Count | 3,988 | 1,229 | $7.61 | $30K |
| 85610 Clinical Chemistry | 67 | 15 | $4.20 | $281 |
| 81003 Clinical Chemistry | 49 | 40 | $2.20 | $108 |
Medicare prescription drug claims, 2024
In 2024, the drug Susmitha Apuri prescribed most often to Medicare patients was Letrozole, with 165 prescriptions and refills. In total Susmitha Apuri wrote 1,741 Medicare prescriptions that cost $5.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 165 | 396 | 56 | $4,580 |
| Anastrozole Generic | 120 | 318 | 42 | $2,794 |
| Ondansetron Odt Ondansetron | 117 | 121 | 79 | $8,323 |
| Jakafi Ruxolitinib Phosphate | 73 | 73 | Under 11 | $1.1M |
| Gabapentin Generic | 71 | 89 | 31 | $927 |
| Prochlorperazine Maleate Generic | 60 | 64 | 46 | $1,675 |
| Eliquis Apixaban | 59 | 71 | 18 | $40K |
| Revlimid Lenalidomide | 49 | 49 | Under 11 | $795K |
| Dexamethasone Generic | 47 | 65 | 20 | $1,027 |
| Hydroxyurea Generic | 44 | 94 | 19 | $1,053 |
| Oxycodone Hcl Generic | 44 | 44 | 24 | $513 |
| Tamoxifen Citrate Generic | 39 | 103 | 11 | $1,498 |
| Prednisone Generic | 31 | 31 | 13 | $162 |
| Duloxetine Hcl Generic | 31 | 37 | Under 11 | $1,960 |
| Xarelto Rivaroxaban | 31 | 53 | Under 11 | $28K |
Brand drugs: 433 claims; generic drugs: 1,308 claims; opioid claims: 133.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Susmitha Apuri $2,489 ($2,489 in general payments such as food, travel and fees) from 36 companies. The largest payer was Novartis Pharmaceuticals Corporation with $306.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 18 | $306 |
| E.R. Squibb & Sons, L.L.C. BMY | 12 | $237 |
| Celgene Corporation BMY | 8 | $201 |
| Incyte Corporation INCY | 8 | $177 |
| Gilead Sciences, Inc. GILD | 5 | $152 |
| Eisai Inc. 4523.T | 8 | $146 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 5 | $126 |
| Genzyme Corporation SNY | 5 | $121 |
| Merck Sharp & Dohme LLC MRK | 5 | $104 |
| Pfizer Inc. PFE | 4 | $82.36 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.